서브메뉴
검색
Innovating With Trust: Regulation and Organizational Field Maturity in the Era of Emerging Health Technologies
Innovating With Trust: Regulation and Organizational Field Maturity in the Era of Emerging Health Technologies
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20260202105218
- ISBN
- 9798291565933
- DDC
- 614
- 서명/저자
- Innovating With Trust: Regulation and Organizational Field Maturity in the Era of Emerging Health Technologies
- 발행사항
- [Sl] : University of Michigan, 2025
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2025
- 형태사항
- 186 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 87-03, Section: A.
- 주기사항
- Advisor: Platt, Jodyn.
- 학위논문주기
- Thesis (Ph.D.)--University of Michigan, 2025.
- 초록/해제
- 요약This dissertation examines how trust in emerging healthcare technologies can be built through organizational and regulatory strategies that advance maturity in technologically-driven fields. Using artificial intelligence (AI) and Precision Oncology (PO) as case studies, this research explores the relationships between governance, organizational field dynamics, regulation, and public trust through three empirical studies.Chapter 2 analyzes how health policy and governance influence trust in healthcare AI through a nationally representative survey of 1,855 adults. Results demonstrate that trust in AI is positively associated with comfort with stakeholders in AI governance (especially physicians, health administrators, and patients; b=0.36, p0.001), while concerns about fast-paced innovation predict lower trust (b=-0.10, p0.001). Perceptions of health law sufficiency and privacy policy clarity significantly moderate these relationships. For those perceiving health laws as insufficient, the positive association between stakeholder comfort and trust in AI is substantially weakened, suggesting that robust legal frameworks are important conditions for trust. Similarly, unclear institutional policies exacerbate the negative relationship between innovation concerns and trust. Demographic analysis shows that women, political independents and uninsured individuals have lower trust in AI, indicating the need for targeted trust-building initiatives. The findings demonstrate the importance of multi-level governance frameworks that drive clear policies and diverse stakeholder engagement.Chapter 3 examines how organizational field mechanisms advance maturity in the emerging field of PO through 34 semi-structured interviews across three academic medical centers (AMCs) and one precision medicine company. Analysis shows that precision medicine companies shape the boundaries of the field by using claiming, demarcating and controlling strategies to establish legitimacy. They complement the needs of established AMC and pharmaceutical companies by offering specialized capabilities, utilizing molecular tumor boards as boundary organizations that facilitate collaboration among competitors within the field. The study also highlights the isomorphic impacts that drive organizational similarities within the field, including FDA regulation, insurance policies, technological infrastructure and professional guidelines. Complementary relationships demonstrate how organizational factors such as specialization, aptitude towards innovative and network ties advance field maturity. Results indicate formalization of practices and organizational roles, suggesting that that the field is advancing from emergence to standardization.Chapter 4 investigates how FDA regulation of companion diagnostics (CDx) shapes the field of PO through 21 interviews of people who work on CDx projects across nine organizations. The study reveals complex regulatory co-creation processes where organizations and FDA regulators collaborate through formal submissions, informal communications, and advocacy coalitions to adapt regulatory frameworks. Organizations experienced structural changes to accommodate regulatory requirements, including expansion of regulatory teams, development of cross-functional mechanisms and systematic learning processes. While participants understood the regulatory benefits of operational guidance, patient safety protections, and quality improvement, they also identified limitations such as inconsistent decision-making, misalignment between regulatory frameworks and clinical implementation, and barriers to innovation through resource-intensive regulatory processes. Participants saw limited public awareness of FDA's diagnostic oversight, suggesting that regulation lacks direct trust-building capacity. However, regulatory approvals signal legitimacy to providers and insurers, potentially building trust through institutional mechanisms.Collectively, these studies demonstrate how building trust in emerging healthcare technologies requires coordinated strategies across multiple levels, combining robust national regulatory frameworks with clear institutional policies, diverse stakeholder engagement and adaptive organizational structures that demonstrate mature capabilities. This work contributes to understanding how organizational and field-level maturity can serve as pathways to trustworthiness, informing future governance and regulatory strategies for emerging healthcare technologies.
- 일반주제명
- Public health
- 일반주제명
- Oncology
- 일반주제명
- Public policy
- 키워드
- Healthcare AI
- 키워드
- Regulation
- 기타저자
- University of Michigan Health Services Organization & Policy
- 기본자료저록
- Dissertations Abstracts International. 87-03A.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008260126s2025 us c eng d■001000017359808
■00520260202105218
■006m o d
■007cr#unu||||||||
■020 ▼a9798291565933
■035 ▼a(MiAaPQ)AAI32271776
■035 ▼a(MiAaPQ)umichrackham006225
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a614
■1001 ▼aHoffman-Peterson, Ariella.
■24510▼aInnovating With Trust: Regulation and Organizational Field Maturity in the Era of Emerging Health Technologies
■260 ▼a[Sl]▼bUniversity of Michigan▼c2025
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2025
■300 ▼a186 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 87-03, Section: A.
■500 ▼aAdvisor: Platt, Jodyn.
■5021 ▼aThesis (Ph.D.)--University of Michigan, 2025.
■520 ▼aThis dissertation examines how trust in emerging healthcare technologies can be built through organizational and regulatory strategies that advance maturity in technologically-driven fields. Using artificial intelligence (AI) and Precision Oncology (PO) as case studies, this research explores the relationships between governance, organizational field dynamics, regulation, and public trust through three empirical studies.Chapter 2 analyzes how health policy and governance influence trust in healthcare AI through a nationally representative survey of 1,855 adults. Results demonstrate that trust in AI is positively associated with comfort with stakeholders in AI governance (especially physicians, health administrators, and patients; b=0.36, p0.001), while concerns about fast-paced innovation predict lower trust (b=-0.10, p0.001). Perceptions of health law sufficiency and privacy policy clarity significantly moderate these relationships. For those perceiving health laws as insufficient, the positive association between stakeholder comfort and trust in AI is substantially weakened, suggesting that robust legal frameworks are important conditions for trust. Similarly, unclear institutional policies exacerbate the negative relationship between innovation concerns and trust. Demographic analysis shows that women, political independents and uninsured individuals have lower trust in AI, indicating the need for targeted trust-building initiatives. The findings demonstrate the importance of multi-level governance frameworks that drive clear policies and diverse stakeholder engagement.Chapter 3 examines how organizational field mechanisms advance maturity in the emerging field of PO through 34 semi-structured interviews across three academic medical centers (AMCs) and one precision medicine company. Analysis shows that precision medicine companies shape the boundaries of the field by using claiming, demarcating and controlling strategies to establish legitimacy. They complement the needs of established AMC and pharmaceutical companies by offering specialized capabilities, utilizing molecular tumor boards as boundary organizations that facilitate collaboration among competitors within the field. The study also highlights the isomorphic impacts that drive organizational similarities within the field, including FDA regulation, insurance policies, technological infrastructure and professional guidelines. Complementary relationships demonstrate how organizational factors such as specialization, aptitude towards innovative and network ties advance field maturity. Results indicate formalization of practices and organizational roles, suggesting that that the field is advancing from emergence to standardization.Chapter 4 investigates how FDA regulation of companion diagnostics (CDx) shapes the field of PO through 21 interviews of people who work on CDx projects across nine organizations. The study reveals complex regulatory co-creation processes where organizations and FDA regulators collaborate through formal submissions, informal communications, and advocacy coalitions to adapt regulatory frameworks. Organizations experienced structural changes to accommodate regulatory requirements, including expansion of regulatory teams, development of cross-functional mechanisms and systematic learning processes. While participants understood the regulatory benefits of operational guidance, patient safety protections, and quality improvement, they also identified limitations such as inconsistent decision-making, misalignment between regulatory frameworks and clinical implementation, and barriers to innovation through resource-intensive regulatory processes. Participants saw limited public awareness of FDA's diagnostic oversight, suggesting that regulation lacks direct trust-building capacity. However, regulatory approvals signal legitimacy to providers and insurers, potentially building trust through institutional mechanisms.Collectively, these studies demonstrate how building trust in emerging healthcare technologies requires coordinated strategies across multiple levels, combining robust national regulatory frameworks with clear institutional policies, diverse stakeholder engagement and adaptive organizational structures that demonstrate mature capabilities. This work contributes to understanding how organizational and field-level maturity can serve as pathways to trustworthiness, informing future governance and regulatory strategies for emerging healthcare technologies.
■590 ▼aSchool code: 0127.
■650 4▼aPublic health
■650 4▼aOncology
■650 4▼aPublic policy
■653 ▼aHealthcare AI
■653 ▼aPrecision Oncology
■653 ▼aRegulation
■653 ▼aCompanion diagnostics
■653 ▼aEmerging health technologies
■690 ▼a0573
■690 ▼a0992
■690 ▼a0769
■690 ▼a0630
■690 ▼a0800
■71020▼aUniversity of Michigan▼bHealth Services Organization & Policy.
■7730 ▼tDissertations Abstracts International▼g87-03A.
■790 ▼a0127
■791 ▼aPh.D.
■792 ▼a2025
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17359808▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.


